2 completed, 1 active not recruiting, 1 not yet recruiting, 1 unknown. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Renal Cell Carcinoma, Clear Cell: new trials by email Literature Review of Renal Cell Carcinoma, Clear Cell trials Research Report on Renal Cell Carcinoma, Clear Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer Ivonescimab (dose level 1) combined with Cadonilimab, Ivonescimab (dose level 2) combined with Cadonilimab, Ivonescimab combined with Ipilimumab - Renal Cell Carcinoma, Clear Cell | Phase 2 | Not yet recruiting | Summit Therapeutics | 100 | 2026-10-19 | 2026-10-16 |
| A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) Drugs Nivolumab, Ipilimumab, BMS-986213 (Relatlimab-Nivolumab FDC) - Renal Cell Carcinoma, Clear Cell | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 52 | 2025-03-20 | 2026-09-11 |
| A Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma Renal Cell Carcinoma, Clear Cell | Completed | RenJi Hospital | 1200 | 2024-01-01 | 2024-10-24 | |
| Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors XmAb®808, Keytruda® (pembrolizumab) - Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma | Phase 1 | Completed | Xencor, Inc. | 60 | 2022-12-14 | 2025-08-07 |
| Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma Pembrolizumab plus denosumab - Renal Cell Carcinoma, Clear Cell, Metastatic Kidney Cancer | Phase 2 | Unknown | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 59 | 2017-12-12 | 2023-03-29 |
Carcinoma, Renal Cell (5) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Kidney Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Adenocarcinoma (5) · Carcinoma (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Kidney Diseases (5) · Male Urogenital Diseases (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Urologic Diseases (5) · Urologic Neoplasms (5) · Kidney Neoplasms (4)
Ipilimumab (2) · pembrolizumab (2) · Denosumab (1)
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (1) · M.D. Anderson Cancer Center (1) · RenJi Hospital (1) · Summit Therapeutics (1) · Xencor, Inc. (1)
United States (3) · China (2) · Australia (1)
Eric Jonasch, MD (1) · Mira Kistler, MD (1)